EasyM, blood test for residual myeloma activity, certified in US
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
News
Fatty acid-binding proteins may be potential target for myeloma
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
Prominent voices to help spotlight myeloma risk in Black communities
Janssen and radio host and comedian D.L. Hughley are partnering to call attention to multiple myeloma in Black communities, with a goal of…
Goal of Myeloma Action Month? Telling the community’s stories.
For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the…
Elranatamab under FDA priority review for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed…
IASO Biotherapeutics’ CAR T-cell therapy gets fresh FDA support
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Abecma cuts worse outcomes risk in half in hard-to-treat myeloma cases
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma…
Free International Myeloma Foundation forum is back in March
Following a three-year hiatus due to the COVID-19 pandemic, the Patient and Family Seminar hosted by the International Myeloma Foundation (IMF) will return…
Worse Prognosis Found for Obese, Underweight Myeloma Patients
Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with…
CARsgen, Huadong Reach Deal to Commercialize CT053 in China
Huadong Medicine has been granted the exclusive rights in China to commercialize CT053, CARsgen Therapeutics’ investigational cell therapy for people with relapsed or…
